Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Trial Profile

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

Recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Feb 2019

At a glance

  • Drugs Ensartinib (Primary) ; Erdafitinib (Primary) ; Larotrectinib (Primary) ; LY 3023414 (Primary) ; Olaparib (Primary) ; Selumetinib (Primary) ; Tazemetostat (Primary) ; Vemurafenib (Primary)
  • Indications CNS cancer; Ependymoma; Ewing's sarcoma; Germ cell and embryonal neoplasms; Glioma; Hepatoblastoma; Langerhans cell histiocytosis; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
  • Focus Therapeutic Use
  • Acronyms Pediatric MATCH
  • Most Recent Events

    • 24 Sep 2018 According to an Epizyme media release, the U.S. FDA has lifted the partial clinical hold that had paused U.S.-based enrollment of new patients in its tazemetostat clinical trials. The company is now in the process of reopening enrollment in all of its company-sponsored trials in the U.S., including the follicular lymphoma (FL) EZH2 activating mutation cohort of its Phase 2 non-Hodgkin lymphoma trial.
    • 24 Sep 2018 Status changed from suspended to recruiting, according to an Epizyme media release.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top